Drug-related hepatotoxi:ity is a~u~common occurrence; Its true InCIdence is difficultto determine.' Despite this, a significant number of drugs have been shown to cause hepatotoxicity. Because thereare few clinical or laboratory manifestations that may specifically link liver injury with medication use, a temporal relationship between the initiation" of a drug and liver injury and resolution of symptoms following withdrawal of the drug becomesextremelyimportant.' Tobramycin is morecommonly associated with neurotoxicity (vestibular and auditory)and nephrotoxicity, although elevation in hepatic enzyme levels is reported as a possible adverse effect of its use,' To date, no case reports of tobramycininduced hepatotoxicity have been published; however, historical data from tertiary sources reveal the possibility of aminoglycoside-induced hepatotoxicity,' We presenta case of liver injury following administration of tobramycin.:
sistant Staphylococcus aureus endocarditis and anxiety.
Surgical history included open reduction and internal fixation of her right femur in 2005 with methicillin-susceptible S. aureusosteomyelitis and cellulitis and a tricuspid valve replacement in 2004. The patient reported a history of illicit intravenous drug abuse prior to 2004 and rare alcohol use. Her home medications included paroxetine 40 mg daily, alprazolam I mg twice daily, metoclopramide 10 mg as needed, and hydrocodone/acetaminophen 7.5 mg/325 mg every 4-6 hours as needed. She had no known drug allergies.
Two blood cultures performed on samples obtained on the patient's arrival were positive for Pseudomonas aeruginosa. Magnetic resonance imaging of the right lower extremity revealed some abnormal intensity in the right distal femur, correlating with osteomyelitis. Hepatitis A, B, and C serologic tests were nonreactive and HIV testing was negative. Other laboratory values are shown in Tables I and 2 . The patient's home medications, except for metoclopramide, were continued on admission. Drug therapy during hospitalization included hydromorphone 0.5-1 mg, oxycodone/acetaminophen 5 mg/325 mg, promethazine 125 mg, docusate sodium 100 mg, and immediate-release oxycodone 5 mg. Empiric antibiotic therapy was started with intravenous piperacillin/tazobactam 3.375 g'every 6 hours, intravenous vancomycin 1 g every 12 hours, and intravenous ciprofloxacin 400 mg every 12 hours. Upon the return of the susceptibility patterns, therapy was changed on hospital day 3 to intravenous ceftazidime 2 g every 8 hours and intravenous tobramycin 70 mg every 8 hours.
Liver enzyme levels increased daily over the following 3 days ( Figure 1 ). Total bilirubin and albumin decreased slightly during this time. Alkaline phosphatase initially declined, but began to rise on day 4. By day 6, there was a persistent elevation in liver enzymes and drug-induced hepatotoxicity was considered. Ceftazidime was considered the primary suspect for hepatotoxicity; it was discontinued on hospital day 8 and therapy with intravenous piperacillin/tazobactam 4.5 g every 6 hours was started. That same day, the tobramycin dose was increased to 100 mg intravenously every 8 hours. Due to a continued increase in aspartate aminotransferase and alanine aminotransferase levels between days 8 and 10, piperacillin/ tazobactam was discontinued and intravenous aztreonam 2 g every 8 hours was started. Although total bilirubin initially decreased, it began to rise on day 8 and peaked at day 12, with alkaline phosphatase peaking on day 8.
Despite the discontinuation of piperacillin/tazobactam and ceftazidime, there was a continued dramatic elevation in liver enzymes; all antibiotics were stopped on day 12. On hospital day 14, total bilirubin and alkaline phosphatase began declining; on day 16, antibiotic therapy was restarted with intravenous aztreonam 2 g every 8 hours and intravenous ciprofloxacin 400 mg every 8 hours. Liver enzymes continued to trend downward and all laboratory values had returned to baseline prior to the patient's discharge on day 19. Total bilirubin and alkaline phosphatase decreased to lower than baseline values; ALT remained slightly above baseline. Oral ciprofloxacin 750 mg twice daily was continued for an additional 8 weeks. 
Table1. Laboratory Values

Discussion
Nephrotoxicity and neurotoxicity are the adverse events most commonly associated with aminoglycosides. This case illustrates a possible occurrence of tobramycin-induced hepatotoxicity. The patient presented with an active infection, bilirubinuria, and mildly elevated total bilirubin, alkaline phosphatase, and aspartate aminotransferase. Although this patient's medical history did not include liver dysfunction, laboratory values including total bilirubin, international normalized ratio, alkaline phosphatase, and albumin were abnormal upon admission, indicating underlying liver disease. Urobilinogen was also initially elevated; however, it returned to normal less than 12 hours after admission (a level of 2.0 is considered trace amounts by our institution's laboratory). This decrease may have been due to the initiation of antibiotics. Alkaline phosphatase and aspartate aminotransferase were also mildly elevated upon admission. While this was also suggestive of liver dysfunction, the elevation in alkaline phosphatase may have been due to osteomyelitis. This patient denied a history of alcohol use but reported a distant history of intravenous cocaine abuse, which may have contributed to the underlying liver dysfunction. It would not be expected that this level of liver dysfunction would put her at a greater risk of experiencing drug-induced hepatotoxicity; however, females tend to have increased susceptibility} Upon initiation of empiric antibiotic therapy, liver enzymes remained stable. Figure 1 shows the strong correlation between the initiation of tobramycin and the elevation of liver enzyme levels. This persistent elevation, despite discontinuation of antibiotics more commonly recognized as offenders, such as ceftazidime and piperacillin/tazobac- tam, reinforces the likelihood of tobramycin-induced hepatotoxicity. Both ceftazidime and piperacillin/tazobactam were discontinued 3-5 days before the spike in liver enzymes,and piperacillin/tazobactarn was restarted afterpersistent elevation of liver enzymes. Given the short halflivesof thesedrugs,there is a low probability of a delayed hepatotoxicity reaction. Other antibiotics used were excluded by the same timeline,or in the instanceof aztreonam,by rechallenge. Nondrug causes of hepatotoxicity wereevaluated throughout the patient's hospital stay. An ultrasound of the right upper quadrant, performed on admission, revealed only nonspecific gallbladder thickening. A follow-up computed tomography scan on hospital day 11 showed no specific findings. Viral hepatitis was excluded by negative serologic tests for hepatitis A, B, and C, along with a negative HIV panel. However, given the time-lagbetween time of infection and positive testing, it is possible that the patient may havebeen infected recently.
Evaluation of the case, using the Naranjo probability scale,indicated a possible relationship between hepatotoxicity and tobramycin therapy in our patient,'Liverenzymes increased whentobramycin was initiated andresolved upon discontinuation of therapy. Additionally, when the tobramycin dosewas increased, subsequent liverenzyme levels weremarkedly increased. Tobramycin concentrations attained during admission wereneversupratherapeutic. Other medication-related causes wereruled out,as thetimeline associated withtheiradministration did notcorrelate withthe rise in liver enzymes and the patient reported taking all home medications as prescribed priorto admission.
Although the Naranjo scale is the most commonly used method of calculating adverse event probability, other methods specific for the evaluationof drug-induced liver disease are available. The accuracy of the Naranjo probabilityscale, when used to evaluate drug-induced liverdisease, was questioned by Garcia-Cortes et aI.' They discussed the discrepancy found when evaluating cases of drug-induced liverdisease on the Naranjo scale versus the Council for International Organizations of Medical Sciences (ClaMS)' or the Maria and Victorino (M&V)8 scales. Depending on the scale used, the categorized likelihood of drug-induced reaction can change. When evaluated on the ClaMS scale, our casehad a score of 8, corresponding with a probable likelihood of tobramycin-induced hepatotoxicity; whenassessed on the M&V scale,our casescored 15,also corresponding with a probable likelihood. .
Our patient was not rechallenged with tobramycin due to the highly suggestive timeline present, lack of specific symptoms, and unnecessary risk. The patientdid not have symptoms common with liver injuries, such as rash or eosinophilia; however, she was febrile at various times throughout admission. These fevers were likely due to osteomyelitis and bacteremia.
The mechanism of hepatic injury withtobramycin is unclear.Currently, no dosage adjustments are necessary for hepatic insufficiency and the primaryroute of elimination is renal (60-85%). In addition to renal clearance, other routes of elimination include feces (35-79%) and bile (minimal amount),"
Conclusions
Although no other case reportson this interaction have beenpublished, practitioners cannotrule out the possibility of tobramycin-induced hepatotoxicity. Early recognition and dose changes or drug withdrawal may preventunnecessary intervention or permanent damage. RFSUMEN DELCASO: Una paciente de 20 afios ingres6 en el hospital para recibirtratamiento por bacteriemia y osteomielitis causadapor Pseudomonas aeruginosa. Se comenz6 terapiaantibi6tica intravenosa empfrica con piperacilina/tazobactam, vancomicina, y ciprofloxacino y tras losresultados de cultivoy sensibilidad se modific6 el tratamiento a ceftazidima y tobramicina 70 mg intravenoso cada8 horasal tercerdfa de hospitalizaci6n. Posteriormente los niveles de enzimashepaticas se incrementaron durante los dfas3-6. Los analisis de hepatitis A, B, YC fueron todos no-reactivos y la pruebade VIHfue negativa. En el dfa 8, se cambi6el tratamiento con ceftazidima a piperacilina/tazobactam y se increment61a dosisde tobramicina a 100mg cada8 horas.Debidoa un aumento continuo delnivel de bilirrubina total,aspartato aminotransferasa, y alanina aminotransferasa, se retir6el tratamiento con piperacilina/ tazobactam y se comenz6 con aztreonam en el dfa 10.EIdfa 12se interrumpi6 la terapia antibi6tica y los parametres hepaticos elevados comenzaron a descender. Se reinici6 el tratamiento con aztreonam y ciprofloxacino el dfa 16,y la mayorfa de los resultados de laboratorio volvieron a los niveles basales el ilia 19;el nivelde bilirrubina totaly de fosfatasa alcalina descendi6 hastavalores inferiores a los basales. 
